RFA治疗大肝癌临床疗效分析
摘要
目的:探讨影响大肝癌射频消融临床疗效的因素。
方法:收集2001年6月至2005年9月某肿瘤医院经射频消融治疗(RFA)的大肝癌51例;RFA前超声引导下行肝穿刺活检取样,采用POWERVISION~(TM)免疫组织化学S-P法检测肝癌热休克蛋白-70(HSP-70)的表达情况;全部病例采用RITA射频肿瘤消融系统1500型治疗机治疗,功率150w,RF发生器频率为460kHz。术后随访患者生存情况。应用SPSS11.5统计软件进行统计分析肝癌HSP-70、肝癌临床分期、肿瘤灭活状态、肝功能(child-pugh)分级、AFP含量、肿瘤分布等因素与大肝癌RFA的临床疗效的关系。
结果:
1、51例大肝癌经射RFA治疗后完全灭活率54.9%(28例),部分灭活率45.1%(23例)。RFA治疗后完全灭活者半年、一年、二年及三年生存率分别为54.9%、31.3%、13.7%和9.8%。部分灭活者半年、一年、二年和三年生存率分别是41.1%、15.8%、9.8%和0%,完全灭活病例的疗效明显优于部分灭活病例的疗效,肿瘤灭活率越高,RFA效果越好,p＜0.05。
2、51例原发性肝癌HSP-70的阳性表达指数高于2的78.43%,正常肝组织中的HSP-70阳性表达指数高于2的46.7%,肝癌组织HSP-70的表达明显高于正常肝组织中的表达,P＜0.05。在HSP-70表达指数≤2的19例中,RFA治疗后半年、一年、二年和三年的生存率分别为100.0%、47.37%、36.84%和15.79%;表达指数＞2的32例患者,RFA治疗后半年、一年、二年和三年生存率分别是93.80%、46.88%、15.63%和3.92%,HSP-70表达指数越高则RFA疗效越差,反之,疗效越好,RFA治疗的疗效与HSP-70表达指数有关,P＜0.05。
3、41例Ⅱ-Ⅲ期肝癌患者RFA治疗后半年、一年、二年和三年的生存率分别是80.3%、41.1%、23.5%和9.8%,10例Ⅳ期肝癌RFA治疗后半年、一年、二年和三年的生存率为15.6%、5.9%、0%及0%,临床分期越晚,RFA治疗效果越差,p＜0.05。
4、肿瘤分布1个肝段者37例,多肝段14例,RFA治疗后半年、一年、二年和三年的生存率与肿瘤分布部位无关,p＞0.05,。
5、AFP＜20μg/L为7例,20μg/L～500μg/L为29例,＞500μg/L为15例,随着AFP水平的升高,RFA治疗效果越差,p＜0.05。
6、肝功能A级25例,B级25例,C级1例,肝功能分级与RFA疗效有关,p＜0.05。
结论:
一、RFA可作为大肝癌治疗的一种补充手段,在无手术指证或不愿意接受手术治疗的肝癌患者只要条件允许,可选择RFA治疗。
二、肝癌组织内HSP-70的表达水平、肝癌临床分期、肝功能分级、肿瘤灭活情况、AFP表达情况是影响大肝癌RFA治疗效果的因素。肝内肿瘤分布的位置对RFA治疗效果无明显影响。由HSP-70表达水平、肝癌临床分期、肝功能分级、肿瘤灭活情况、AFP表达情况可以预测RFA治疗大肝癌的疗效。
Objective: To explore factors that can influence the clinical effect of radiofrequency ablation(RFA) of liver cancer.
Methods: 51 liver cancer cases that were treated with RFA were collected from cancer hospital between Jun. 2001 and Sept. 2005; liver biopsy was conducted with the help of ultrasound before RFA, HSP-70 expression was determined by POWERVISION~(TM) immunohistochemistry S-P method; all cases used RITA 1500 RFA machine: Power: 150W; Frequency: 460 kHz. The survival was followed up after the operation. The relationship among HSP-70 of live cancer, clinical classification of live cancer, inactive state of tumor, classification of live function, expression of AFP, tumor distribution and clinical effect of live cancer RFA were analyzed by SPSS11.5 statistical software.
Results:
1. The ratio of complete inactivation from 51 liver cancer cases treated with RAF is 54.9%(28 cases), while the ratio of partial inactivation is 45.1%(23 cases). The survival rate of complete inactivation after RFA in half a year, one year, two years and three years are 54.9%、31.3%、13.7% and 9.8% respectively. The survival rate of partial inactivation after RFA in half a year, one year, two years and three years are 41.1%、15.8%、9.8% and 0% respectively. The effect of complete inactivation is better than that of partial inactivation. The higher of tumor inactivation ratio, the better effect of RFA, P<0.05.
2. HSP-70 positive expression index of 78.43% from 51 liver cancer patients is higher than 2. HSP-70 positive expression index of 46.7% from normal live tissue is higher than 2. The expression of HSP-70 in live cancer is higher than in normal live tissue, P<0.05. In 19 cases whose index of HSP-70 expression are less than 2, the survival rate are 100.0%, 47.37%, 36.84% and 15.79 respectively after RFA half year, one year, two years and three years; In 32 patients whose expression index is more than 2, the survival rate are 93.80%, 46.88%, 15.63% and 3.92% respectively after RFA half year, one year, two years and three years. The higher HSP-70 expression index, the worse the effect of RFA. There is relationship between the effect of RFA and The expression index of HSP-70.
3. The survival rate of 41 liver cancer patients stagedⅡ-Ⅲwho were treated by RFA in half a year, one year, two years and three years are 80.3%、41.1%、23.5% and 9.8%, and survival rate of 10 liver cancer patients staged IV who were treated by RFA in half a year, one year, two years and three years are 15.6%、5.9%、0% and 0%. The higher of liver cancer clinical classification is, the worse of effect of RFA is, P<0.05.
4. 37 patient with the tumor distributed in one hepatic segment, and 14 with the tumor distributed in multi-hepatic segments, the survival rate is unrelated with tumor distribution after treated with RFA half a year, one year, two years and three years, p<0.05.
5. The expression of AFP in 7 patients is less than 20μg/L (except negative patients) , in 29 patients is between 20μg/L and 500μg/L, and in 15 patients is more than 500μg/L, the effect of RFA is getting worse as AFP gets higher, p<0.05.
6. Liver function of 25 patients is A degree, of 25 patients is B degree and of 1 patient is C degree. Child-Pugh is related to the effect of RFA,p<0.05.
Conclusion:
1. RFA can be an additional therapy of liver cancer. RFA treatment can be chosen when the liver cancer patients have no indications of operation or the patient is not willing to operation.
2. HSP-70 expression level of liver cancer, clinical classification of liver cancer, inactive state of tumor, classification of liver function, the expression of AFP are the factors that affect influence the clinical effect of RFA of liver cancer. Tumor distribution have no relationship with the effect of RFA of liver cancer. The effect of RFA of liver cancer can be predicted from HSP-70 expression level of liver cancer, clinical classification of liver cancer, inactive state of tumor, classification of liver function, the expression of AFP.
方法:收集2001年6月至2005年9月某肿瘤医院经射频消融治疗(RFA)的大肝癌51例;RFA前超声引导下行肝穿刺活检取样,采用POWERVISION~(TM)免疫组织化学S-P法检测肝癌热休克蛋白-70(HSP-70)的表达情况;全部病例采用RITA射频肿瘤消融系统1500型治疗机治疗,功率150w,RF发生器频率为460kHz。术后随访患者生存情况。应用SPSS11.5统计软件进行统计分析肝癌HSP-70、肝癌临床分期、肿瘤灭活状态、肝功能(child-pugh)分级、AFP含量、肿瘤分布等因素与大肝癌RFA的临床疗效的关系。
结果:
1、51例大肝癌经射RFA治疗后完全灭活率54.9%(28例),部分灭活率45.1%(23例)。RFA治疗后完全灭活者半年、一年、二年及三年生存率分别为54.9%、31.3%、13.7%和9.8%。部分灭活者半年、一年、二年和三年生存率分别是41.1%、15.8%、9.8%和0%,完全灭活病例的疗效明显优于部分灭活病例的疗效,肿瘤灭活率越高,RFA效果越好,p＜0.05。
2、51例原发性肝癌HSP-70的阳性表达指数高于2的78.43%,正常肝组织中的HSP-70阳性表达指数高于2的46.7%,肝癌组织HSP-70的表达明显高于正常肝组织中的表达,P＜0.05。在HSP-70表达指数≤2的19例中,RFA治疗后半年、一年、二年和三年的生存率分别为100.0%、47.37%、36.84%和15.79%;表达指数＞2的32例患者,RFA治疗后半年、一年、二年和三年生存率分别是93.80%、46.88%、15.63%和3.92%,HSP-70表达指数越高则RFA疗效越差,反之,疗效越好,RFA治疗的疗效与HSP-70表达指数有关,P＜0.05。
3、41例Ⅱ-Ⅲ期肝癌患者RFA治疗后半年、一年、二年和三年的生存率分别是80.3%、41.1%、23.5%和9.8%,10例Ⅳ期肝癌RFA治疗后半年、一年、二年和三年的生存率为15.6%、5.9%、0%及0%,临床分期越晚,RFA治疗效果越差,p＜0.05。
4、肿瘤分布1个肝段者37例,多肝段14例,RFA治疗后半年、一年、二年和三年的生存率与肿瘤分布部位无关,p＞0.05,。
5、AFP＜20μg/L为7例,20μg/L～500μg/L为29例,＞500μg/L为15例,随着AFP水平的升高,RFA治疗效果越差,p＜0.05。
6、肝功能A级25例,B级25例,C级1例,肝功能分级与RFA疗效有关,p＜0.05。
结论:
一、RFA可作为大肝癌治疗的一种补充手段,在无手术指证或不愿意接受手术治疗的肝癌患者只要条件允许,可选择RFA治疗。
二、肝癌组织内HSP-70的表达水平、肝癌临床分期、肝功能分级、肿瘤灭活情况、AFP表达情况是影响大肝癌RFA治疗效果的因素。肝内肿瘤分布的位置对RFA治疗效果无明显影响。由HSP-70表达水平、肝癌临床分期、肝功能分级、肿瘤灭活情况、AFP表达情况可以预测RFA治疗大肝癌的疗效。
Objective: To explore factors that can influence the clinical effect of radiofrequency ablation(RFA) of liver cancer.
Methods: 51 liver cancer cases that were treated with RFA were collected from cancer hospital between Jun. 2001 and Sept. 2005; liver biopsy was conducted with the help of ultrasound before RFA, HSP-70 expression was determined by POWERVISION~(TM) immunohistochemistry S-P method; all cases used RITA 1500 RFA machine: Power: 150W; Frequency: 460 kHz. The survival was followed up after the operation. The relationship among HSP-70 of live cancer, clinical classification of live cancer, inactive state of tumor, classification of live function, expression of AFP, tumor distribution and clinical effect of live cancer RFA were analyzed by SPSS11.5 statistical software.
Results:
1. The ratio of complete inactivation from 51 liver cancer cases treated with RAF is 54.9%(28 cases), while the ratio of partial inactivation is 45.1%(23 cases). The survival rate of complete inactivation after RFA in half a year, one year, two years and three years are 54.9%、31.3%、13.7% and 9.8% respectively. The survival rate of partial inactivation after RFA in half a year, one year, two years and three years are 41.1%、15.8%、9.8% and 0% respectively. The effect of complete inactivation is better than that of partial inactivation. The higher of tumor inactivation ratio, the better effect of RFA, P<0.05.
2. HSP-70 positive expression index of 78.43% from 51 liver cancer patients is higher than 2. HSP-70 positive expression index of 46.7% from normal live tissue is higher than 2. The expression of HSP-70 in live cancer is higher than in normal live tissue, P<0.05. In 19 cases whose index of HSP-70 expression are less than 2, the survival rate are 100.0%, 47.37%, 36.84% and 15.79 respectively after RFA half year, one year, two years and three years; In 32 patients whose expression index is more than 2, the survival rate are 93.80%, 46.88%, 15.63% and 3.92% respectively after RFA half year, one year, two years and three years. The higher HSP-70 expression index, the worse the effect of RFA. There is relationship between the effect of RFA and The expression index of HSP-70.
3. The survival rate of 41 liver cancer patients stagedⅡ-Ⅲwho were treated by RFA in half a year, one year, two years and three years are 80.3%、41.1%、23.5% and 9.8%, and survival rate of 10 liver cancer patients staged IV who were treated by RFA in half a year, one year, two years and three years are 15.6%、5.9%、0% and 0%. The higher of liver cancer clinical classification is, the worse of effect of RFA is, P<0.05.
4. 37 patient with the tumor distributed in one hepatic segment, and 14 with the tumor distributed in multi-hepatic segments, the survival rate is unrelated with tumor distribution after treated with RFA half a year, one year, two years and three years, p<0.05.
5. The expression of AFP in 7 patients is less than 20μg/L (except negative patients) , in 29 patients is between 20μg/L and 500μg/L, and in 15 patients is more than 500μg/L, the effect of RFA is getting worse as AFP gets higher, p<0.05.
6. Liver function of 25 patients is A degree, of 25 patients is B degree and of 1 patient is C degree. Child-Pugh is related to the effect of RFA,p<0.05.
Conclusion:
1. RFA can be an additional therapy of liver cancer. RFA treatment can be chosen when the liver cancer patients have no indications of operation or the patient is not willing to operation.
2. HSP-70 expression level of liver cancer, clinical classification of liver cancer, inactive state of tumor, classification of liver function, the expression of AFP are the factors that affect influence the clinical effect of RFA of liver cancer. Tumor distribution have no relationship with the effect of RFA of liver cancer. The effect of RFA of liver cancer can be predicted from HSP-70 expression level of liver cancer, clinical classification of liver cancer, inactive state of tumor, classification of liver function, the expression of AFP.
引文
[1]Lam CM,Ng KK,Poon,et al.Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre[J].British Journal of Surgery,2004,91:334-338.
[2]Poon RT ST,Lo CM et al.Improving survival results after resection of hepatocellular carcinoma:a prospective study of 377 patients over 10 years[J].Annals of Surgery,2001,234:63-70.
[3]Fong Y RL,Jarnagin W,et al.An analysis of 412 cases of hepatocellular carcinoma at a Western center[J].Annals of Surgery,1999,229:790-799.
[4]OtaK,Teraoka S,Kawai T,et al.Donor difficulties in Japan and Asian countries[J].Transplantation Proceedings,1995,27:83-86.
[5]El Serag,HB Mason AC.Rising incidence of hepatocellular carcinoma jin the United States[J].New England Journsl of Medicine 1999,340:745-750.
[6]Radons I,Multhoff G..Immunostimulatory functions of membrane-bound and exported heat shock protein 70[J].Exerc Immunol Rev,2005,11:17-33.
[7]Beere HM,Green DR.Stressmanagement heat shock protein-70 and the regulation of apop tosis[J].Trends Cell Biol,2001,11(1):6-10.
[8]Didelot C,Schmitt E,BrunetM,et al.Heat shock proteins:endogenousmodulators of apop totic cell death[J].Handb Exp Pharmacol,2006,172:171-198.
[9]Yenari MA,LIU I,Zheng Z,et al.Antiapop totic and anti-inflammatory mechanisms of heat-shock protein protection[J].Ann Nyacad Sci,2005,1053:74-83.
[10]胡沛臻,杨守京,马福成等.人原发性肝细胞癌中热休克蛋白70 mRNA的表达[J].诊断病理学杂志,2001,8:220-222.
[11]尹燕明,秦庆亮,张伟,赵晶,张长丽,于建国等.肝细胞癌热休克蛋白70过表达与白发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-85.
[12]陈敏华,严昆,戴莹,等.灰阶超声造影新技术对肝肿瘤诊断及射频治疗的应用价值[J].中国医学影像技术,2004,20:326-330
[13]陈敏华,严昆.新型造影剂与灰阶超声造影技术对肝肿瘤的诊断价值[J].中华超声影像学杂志,2004,13:38-42
[14]Quaia E,BertolottoM,ForgacsB,et al.Detection of livermetastases by pulse inversion harmonic imaging during Levovist late phase:comparison with conventional ultrasound and helical CT in 160 patients[J].Eur Radiol,2003,13:475-483.
[15]Isozaki T,Numata K,Kiba T,et al.Differential diagnosis of hepatic-Gritzmann N.Small hepatocellular carcinomas in patients with liver cirrhosis:potentials and limitations of contrast-enhanced power Doppler sonography[J].Eur J Gastroenterol Hepatol,2003,15:881-883
[16]Liu JC,Chiou HJ,Chen WM,et al.Sonographically guided core needle biopsy of soft tissue neop lasms[J].Clin Ultrasound,2004,32:294-298.
[17]Livraghi T,Solbiati L,Meloni MF,et al.Treatment of focal liver tumors with percutaneous radio2frequency ablation:complications encountered in a multicenter study.Radiology,2003,226:441-451.
[18]McGahan J P,Browning PD,Brock J M,et al.Hepaticablationusing ra diofrequency electrocautery[J].Invest Radiol,1990,25:267-270.
[19]SanchezH,vanSonnenbergE,D 'agostineH,etal.Percutaneoustissue ablation by radiofrequencythermalenergyasapreliminarytotumorablation.MinimlnvasiveTher,1993,2:299-305.
[20]Kim JH,Chung JW,Han JK,et all Transcatheter arterial embolization of the internal mammary artery in hepatocellular carcinoma[J].J Vasc Interv Radiol,1995,6(1):71-77
[21]Park SI,Lee DY,Won JY,et al1 Extrahepatic collateral supply of hepatocellular carcinoma by the intercostal arteries[J].Vasc Interv Radiol,2003,14(4):461-468
[22]Chung JW,Park JH,Han JK,et all Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma:the safety and potential therapeutic role[J].Vasc Interv Radiol,1998,9(3):495-500
[23]邓小玲,陈玮,蔡美英等.原发性肝癌HSP70和MHC Ⅰ类分子的表达[J].临床肝胆病杂志,2003,19:59-60.
[24]El Serag,HB Mason AC Rising incidence of hepatocellular carcinoma jin the United States[J].New England Journsl of Medicine 1999;340:745-750.
[25]尹燕明,秦庆亮,张伟,等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-85.
[26]Solbiati L,Ierace T,Goldberg SN,et al.Percutaneous US-guided radio frequency tissue ablation of liver metastases:treatment and follow upin 16patients[J].Radiology,1997,202:195-203.
[27]Livraghi T,Goldberg SN,Lazzaroni S,et al,Small heptecellular careinoma:treatment with radio-frequency ablation versus ethanol injection[J].Radiology,1999,210:655-657
[28]Gullo CA,Teoh G.Heat shock proteins:to present or not,that is the question[J].Immunol Lett,2004,94:11-15.
[29]Chuma M,Sakamoto M,Yamazaki K,et al.Expression profiling in multistage hepatocarcinogenesis:identification of HSP70 as a molecular marker of early hepatocellular carcinoma[J].Hepatology,2003,37:198-201.
[30]方磊,胡道予.射频消融治疗肝细胞肝癌的长期疗效[J].放射学实践,2007,22(2):113-115.
[31]Takashima M,Kuramit su Y,Yokoyama Y,et al.Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma[J].Proteomics,2003,3:2487-2489.
[1]Lam CM,Ng KK,Poon,et al.Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre[J].British Joumal of Surgery,2004,91:334-338.
[2]Fong Y RL,Jarnagin W,et al.An analysis of 412 cases of hepatocellular carcinoma at a Western center[J].Annats of Surgery,1999,229:790-799.
[3]El Serag,HB Mason AC Rising incidence of hepatocellular carcinomajin the United States.New England Journsl of Medicine 1999;340:745-50.
[4]Livraghi T,Goldberg SN,Lazzaroni S,et al.hepatocellular carcinoma:radio-frequency ablation of medium and large lesions[J].Radiology,2001,136:864-9.
[5]Chen MH,Yang W,Yan K,et al.Large liver tumors protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model overlapping mode and electrode placement process[J].Radiology,2004,232:260-71.
[6]Bleicher RJ,Allegra DP,Nora DT,et al.Radiofrequency ablation in 447complex unresectable liver tumors:lesson leamed[J].Ann Surge Oncol,2003,10:52-58.
[7]严昆,王艳滨,陈敏华,高文,杨薇,戴莹,尹珊珊.172例肝癌射频消融治疗预后因素分析[J].中华医学杂志,2005,85:2322-2326.
[8]Poon RT,Ng KK,Lam CM,et al.Radiofrequency ablation for subcapsular hepatocellular carcinoma[J].Annals of Surgical Oncology,2004,11:281-9.
[9]Yamamoto J,Kosuge T,Takayama T,et al.Recurrence of hepatocellular carcinoma after surger[J]y.British Journal of surgery,1996,83:1219-22.
[10]Nicoli N,Casaril A,Marchiori L,et al.Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation[J].Journal of Hepatobiliary Pancreatic Surgery,2001,8:417-241.
[11]Elias D,de Baere T,Smayra T,et al.Percutaneous radio,frequency thermoablation as an alternative to surgery fortreatment of liver tumour recurrence after hepatectomy[J].British Journal of Surgery,2002,89:752-6.
[12]Choi D,Lim HK,Kim MJ,et al.Recurrent hepatocellular carcinoma:percutaneous radiofrequency ablation after hepatectomy[J].Radiology,2004,230:135-41.
[13]Bowles BJ,Machi J,Limm WM,et al.Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors[J].Archives of Surgery,2001;136:864-869.
[14]Poon RT,Ng KK,Lam CM,et al.Effectiveness of radiofrequency ablation for hepatocellular carcinoma large than 3cm in diameter[J].Achives of surgery,2004;139:281-287.
[15]陈敏华,杨薇,严昆,高文,戴莹,霍苓,张晖,黄信孚,等.应用射频消融法对肝肿瘤患者进行规范化治疗.中华医学杂志,2005,137:1741-1746.
[16]Wu JY,Chen MH,Yan K,Ultrasound-guided radiofrequency ablation in the treatment of liver metastases[J].Peking Uni,2001,33:449-451.
[17]Poon RT,Fan ST,Ng IO,et al.Significance of resection margin in hepatectomy for hepatocellular carcinoma:A critical reappraisal[J].Annals of surgery,2000,231:544-551.
[18]Regimbeau JM,Kianmanesh R,Farges O,et al.Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma[J].Surgery,2002,131:311-317.
[19]Livraghi T,Solbiati L,Meloni MF,et al.Treatment of liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226:441-451.
[20]De Baere T,Risse O,Kuoch V,et al.Adverse events during radiofrequency treatment of 582 hepatic tumors[J]Roentgenol,2003,181:695-700.
[21]Rhim H,Yoon KH,Lee JM,et al.Major complications after radiofrequency thermal ablation of hepatic tumors:spectrum of imaging finding s[J].Radiographics,2003;23:123-134.
[22] Mulier S, Mulier P, Ni Y, et al.Complications of liver tumours[J] . British Journal of Surgery, 2002; 89: 1206-1222.
[23] Rhim H, Yoon KH, Lee JM, et al. Major complications after radiofrequency thermal ablation of hepatic tumors : spectrum of imaging findings[J]. Radiographics, 2003,23: 123-134.
[24] Mulier S, Mulier P, NiY,et al.Complications of radiofrequency coagulation ofliver tumours[J].Br J Surg, 2002,89: 1206-1222.
[25] Bowles BJ, Machi J, LimmWM, et al. Safety and efficacy of radiofrequency themal ablation in advanced livers tumors . Arch Surg, 2001,136: 864—869.
[26] Meloni MF, Goldberg SN, Moser V, et al. Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J]. Eur J Ultrasound, 2002,1573-1576.
[27] Mulier S, Mulier P, Ni Y, et al.Complications of radiofrequency coagulation of liver tumours .Br J Surg, 2002,89: 1206-1222.
[28] Meloni MF, Goldberg SN, Moser V, et al. Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J]. Eur J Ultrasound, 2002, 77:1573-1576.
[29] Livraghi T, Solbiati L, Meloni MF, et al. Treatment of liver tumors with percutaneous radio-frequency ablation : complications encountered in a multicenter study [J]. Radiology, 2003, 226: 441-451.
[30] Rhim H, Yoon KH, Lee JM, et al. Major complications after radiofrequency thermal ablation of hepatic tumors :spectrum of imaging findings[J]. Radiographics, 2003,23: 123-134.
[31] Bowles BJ, Machi J, Limm WM, et al.Safety and efficacy of radiofrequency themal ablation in advanced livers tumors[J] .Arch Surg, 2001,136: 864-869.
[32] De Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow up of more than lyear[J]. AJR AmJ Roentgenol, 2000, 175: 1619-1625.
[33]Rhim H,Yoon KH,Lee JM,et al.Major complications after radiofrequency thermal ablation of hepatic tumors:spectrum of imaging findings[J].Radiographics,2003,23:123-134.
[34]Meloni MF,Goldberg SN,Moser V,et al.Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J].Eur J Ultrasound,,2002,15:73-76.
[35]戴莹,陈敏华.射频消融在肝肿瘤治疗中的并发症[J].中华外科杂志,2004,42:1193-1195.
[36]Lu DS,Raman SS,Limanond P,et al.lnfluence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors.Journal of Vascular and Interventional Radiology,2003,14:1267-1274.
[37]Kuvshinoff Bw,Ota DM.Radiofrequency ablation of liver tumors:influence of techniqtie and tumor size[J]Surgery,2002;132:605-611.
[38]Siperstein A,Garland A,Engle K,et al.Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors[J].Annals of Surgical Ontology,2000,7:106-113.
[39]Machi J,Uchida S,Sumida K,et al.Ultrasound.guided radio frequency thermal ablation of liver tumors:percutaneous laparoscopic and open surgical approaches[J].Journal of Gastro—intestinal Surgery,2001,5:477-489.
[40]Kosari K,Gomes M,Hunter D,et al.Local intrahepatic and systemic recurrence patterns after radiofiequency ablation of hepatic malignancies[J].Journal of Gastrointestinal Surgery,2002,6:255-263.
[41]arrison LE,Koneru B,Baramipour P,et al.Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma[J]Journal of American College of Surgery,2003,197:759-764.
[42]Hori T,Nagata K,Hasuike S,et al.Risk factors for the local recurrence of heDatOcellular carcinoma after a single session of percutaneous radiofrequency ablation[J].Journa J of Gastroenterology,2003,38:977-981.
[43]Bleicher RJ,Allegra DP,Nora DT,et al.Radiofrequency ablation i11 447 complex unresectable liver tumors:lessons learned[J].Annals of Surgical Oncology,2003,10:52-58.
[44]Komorizono Y,Oketani M,Sako K,et al.Risk factors for local recurrence Of small hepatocellular carcinoma tumors after a single session,single application Of percutaneous radiofrequency ablation[J].Cancer,2003,97:1253-1262.
[45]Elias D,Baton O,Sideris L,et al.Local recurrences after intraoperative radiofrequencv ablation of liver metastases:a comparative study with anatomic and wedge resections[J].Annals of Surgical Oncology,2004,11:500-505.
[46]严昆,陈敏华,杨薇,王艳滨,高文.肝细胞射频消融治疗远期疗效分析[J].中华消化杂志,2006,28:556-558.
[47]Helton WS.Minimizing complications with radiofrequency ablation for liver cancer:the importance of properly controlled clinical trials and standardized reporting[J]Annals of Surgery.2004;239:459-463.
[48]范林军,马宽生,何振平,等.射频消融治疗大肝癌的安全性和近期疗效[J].中国普外基础与临床杂志,2002,9:265-268.
[49]Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular carcinoma:radio-frequency ablation of medium and large lesions[J].Radiology,2000,214:761-768.
[50]张利辉,崔忠,赵清涛,等.射频联合肝动脉栓塞化疗及无水酒精注射治疗不能手术切除肝癌[J].中国普通外科杂志,2002,11:525-527.
[51]Machi J,Uchida S,Sumida K,et al.Ultrasound-guided radiofrequency thermal ablation of liver tumor:percutaneous laparoscopic and open surgical approaches[J].J Gastrointest Surg,2001,5:477-489.
[52]杨薇,陈敏华,严昆,等.射频消融对较大肝肿瘤治疗范围与布针方案计算的研究[J].中华超声影像学杂志,2002,9:265-268.
[53]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治 疗肝细胞癌[J].中华外科杂志,2002,40:826-829.
[54]沈理,陈敏华,严昆,杨薇,高文,廖盛日,杨仁杰等.探讨经皮射频消融联合肝动脉化学栓塞治疗大肝癌的临床应用效果[J].中华超声影像学杂志,2004,13:577-580.
[55]Seegenchmiedt MH,Brady LW,Sauer R.Interstitial thermorad iotherapy:review on technical and clinical aspects.Am[J]Clin Oncol,1990,13:352-363.
[1]Lindquist S.The heat shock response[J].Annu RevBiochem,1986,55:1151-1191.
[2]Heat shock proteins and their characteristics[J].PolMerkrur Lekarski,2005,19(110):215-219.
[3]Sorger PK,LewisMJ,Pelham HR.Heat shock factor is regulated differently in yeast and Hela cells[J].Nature,1987,329(6134):81-84.
[4]Todrvk Sm,Gough M I,Pockley AG.Facets of heat shock protein 70 show immunotherapeutic potential[J].Immunology,2003,110(1):1-9.
[5]胡沛臻,杨守京,马福成,等.人原发性肝细胞癌中热休克蛋白70 mRNA的表达[J].诊断病理学杂志,2001,8:220-223.
[6]尹燕明,秦庆亮,张伟,等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-86.
[7]邓小玲,陈玮,蔡美英,等.原发性肝癌HSP70和MHC Ⅰ类分子的表达[J].临床肝胆病杂志,2003,19:59-61.
[8]Radons I,Multhoff G.Immunostimulatory functions of membrane-bound and exported heat shock protein 70[J].Exerc Immunol Rev,2005,11:17-33.
[9]MaverMP,Bukau B.HSP-70 chaperones:cellular functions and molecular mechanism[J].CellMol Life Sci,2005,62(6):670-684.
[10]Mogk A,Bukau B.Molecular chaperones:structure of a protein disaggregase[J].Curr Biol,2004,20;14(2):R78-80.
[11]van Eden W,van der Zee R,Prakken B.Heat-shock proteins induce T-cell regulation of chronic inflammation[J].Nat Rev Immunol,2005,5(4):318-320.
[12]Molecular chaperones and protein quality control[J].Cell,2006,125(3):443-451.
[13]Cohen JJ.Programmed cell death in the immune system[J].Adv Immunol,1991,50:55-85.
[14]Beere HM,Green DR.Stressmanagement heat shock pro-tein-70 and the regulation of apop tosis[J].Trends Cell Biol,2001,11(1):6-10.
[15]Didelot C,Schmitt E,BrunetM,et al.Heat shock pro teins:endogenousmodulators of apop totic cell death[J].Handb Exp Pharmacol,2006,172:171-198.
[16]YenariMA,L IU I,Zheng Z,et al.Antiapop totic and anti inflammatory mechanisms of heat-shock protein protection[J].Ann N Y Acad Sci,2005,1053:74-83.
[17]Todryk SM,Gough MJ,Pockley A G.Facet s of heatshock protein 70 show immunotherapeutic potential[J].Immunology,2003,110:1-3.
[18] Gross C ,Hansch D , Gastpar R ,et al. Interaction of heat shock protein70 peptide with N K cells involves the N K receptor CD94[J].Biol Chem,2003,384 : 267-269.
[19] Shin BK,Wang H ,Yim AM ,et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function [J]. J BiolChem, 2003 ,278 :7607-7609.
[20] Becket T ,Hartl FU ,Wieland F. CD40 ,an ext racellular receptor for binding and uptake of HSP70-peptide complexes[J]. J Cell Biol ,2002 ,158 (7) :1277-1278.
[21] Wang YF ,Whit tll T ,McGoawan E ,et al. Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells [J] . Immunol , 2005 , 174 :3306-3308.
[22] Ponomarev ED,Tarasenko TN,Sapozlmikov AM.Splenic cvtotoxic cells recognize surface HSP70 on culture-adapted EL24 mouse lymphoma cells [J] . Immunol Lett ,2000,74 (2) :133-135.
[23]Michils A, Redivo M, Zegers2de2Beyl V, et al. Increased expression of high but not low molecular weight heat shock p roteins in respectable lung carcinoma[J]. Lung Cancer, 2001, 33 (1): 59 -67.
[24]Canoz O, Belenli O, Patiroglu T. general features of gastric carcinomas and comparison of HSP70 and NK cell immunoreactivity with p rognostic factors[J]. PathologyOncology Research, 2002, 8 (4) :262-269.
[25]Schueller G, Kettenbach J, Sedivy R, et al. Expression of heat shock p roteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model[J]. Oncol Rep, 2004, 12(3): 495-499.
[26]Schueller G, Kettenbach J, Sedivy R, et al. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo[J]. Int J Oncol, 2004, 24 (3): 609 -613.
[27]Sondermann H, Becker T, Mayhew M, et al. Characterization of a recep tor for heat shock p rotein 70 on macrophages and monocytes[J].Biol Chem, 2000, 381 (12): 1165-1174.
[28]Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apop totic / necrotic tumor cells[J]. Int J Cancer, 2001, 15 (4): 539-548.
[29]Sanchez2Ortiz RF, Tannir N, Ahrar K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radiofrequency ablation of the primary tumor: an in situ tumorvaccine? Urol, 2003,170: 178-179.
[30]Naito Y, Saito K, Shiiba K, et al. CD8 + T cells infiltrated within cancer cells nests as a p rognostic factor in human colorectal cancer [J] .Cancer Res, 1998, 58: 3491-3494.
[31]Noguchi T, Wada S, Takeno S, et al. Lymph node metastasis could be p redicted by evaluation of macrophage infiltration and hsp70 expression in superficial carcinoma of the esophagus[J]. Oncol Rep,2003,10 (5): 1161-1164.
[2]Poon RT ST,Lo CM et al.Improving survival results after resection of hepatocellular carcinoma:a prospective study of 377 patients over 10 years[J].Annals of Surgery,2001,234:63-70.
[3]Fong Y RL,Jarnagin W,et al.An analysis of 412 cases of hepatocellular carcinoma at a Western center[J].Annals of Surgery,1999,229:790-799.
[4]OtaK,Teraoka S,Kawai T,et al.Donor difficulties in Japan and Asian countries[J].Transplantation Proceedings,1995,27:83-86.
[5]El Serag,HB Mason AC.Rising incidence of hepatocellular carcinoma jin the United States[J].New England Journsl of Medicine 1999,340:745-750.
[6]Radons I,Multhoff G..Immunostimulatory functions of membrane-bound and exported heat shock protein 70[J].Exerc Immunol Rev,2005,11:17-33.
[7]Beere HM,Green DR.Stressmanagement heat shock protein-70 and the regulation of apop tosis[J].Trends Cell Biol,2001,11(1):6-10.
[8]Didelot C,Schmitt E,BrunetM,et al.Heat shock proteins:endogenousmodulators of apop totic cell death[J].Handb Exp Pharmacol,2006,172:171-198.
[9]Yenari MA,LIU I,Zheng Z,et al.Antiapop totic and anti-inflammatory mechanisms of heat-shock protein protection[J].Ann Nyacad Sci,2005,1053:74-83.
[10]胡沛臻,杨守京,马福成等.人原发性肝细胞癌中热休克蛋白70 mRNA的表达[J].诊断病理学杂志,2001,8:220-222.
[11]尹燕明,秦庆亮,张伟,赵晶,张长丽,于建国等.肝细胞癌热休克蛋白70过表达与白发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-85.
[12]陈敏华,严昆,戴莹,等.灰阶超声造影新技术对肝肿瘤诊断及射频治疗的应用价值[J].中国医学影像技术,2004,20:326-330
[13]陈敏华,严昆.新型造影剂与灰阶超声造影技术对肝肿瘤的诊断价值[J].中华超声影像学杂志,2004,13:38-42
[14]Quaia E,BertolottoM,ForgacsB,et al.Detection of livermetastases by pulse inversion harmonic imaging during Levovist late phase:comparison with conventional ultrasound and helical CT in 160 patients[J].Eur Radiol,2003,13:475-483.
[15]Isozaki T,Numata K,Kiba T,et al.Differential diagnosis of hepatic-Gritzmann N.Small hepatocellular carcinomas in patients with liver cirrhosis:potentials and limitations of contrast-enhanced power Doppler sonography[J].Eur J Gastroenterol Hepatol,2003,15:881-883
[16]Liu JC,Chiou HJ,Chen WM,et al.Sonographically guided core needle biopsy of soft tissue neop lasms[J].Clin Ultrasound,2004,32:294-298.
[17]Livraghi T,Solbiati L,Meloni MF,et al.Treatment of focal liver tumors with percutaneous radio2frequency ablation:complications encountered in a multicenter study.Radiology,2003,226:441-451.
[18]McGahan J P,Browning PD,Brock J M,et al.Hepaticablationusing ra diofrequency electrocautery[J].Invest Radiol,1990,25:267-270.
[19]SanchezH,vanSonnenbergE,D 'agostineH,etal.Percutaneoustissue ablation by radiofrequencythermalenergyasapreliminarytotumorablation.MinimlnvasiveTher,1993,2:299-305.
[20]Kim JH,Chung JW,Han JK,et all Transcatheter arterial embolization of the internal mammary artery in hepatocellular carcinoma[J].J Vasc Interv Radiol,1995,6(1):71-77
[21]Park SI,Lee DY,Won JY,et al1 Extrahepatic collateral supply of hepatocellular carcinoma by the intercostal arteries[J].Vasc Interv Radiol,2003,14(4):461-468
[22]Chung JW,Park JH,Han JK,et all Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma:the safety and potential therapeutic role[J].Vasc Interv Radiol,1998,9(3):495-500
[23]邓小玲,陈玮,蔡美英等.原发性肝癌HSP70和MHC Ⅰ类分子的表达[J].临床肝胆病杂志,2003,19:59-60.
[24]El Serag,HB Mason AC Rising incidence of hepatocellular carcinoma jin the United States[J].New England Journsl of Medicine 1999;340:745-750.
[25]尹燕明,秦庆亮,张伟,等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-85.
[26]Solbiati L,Ierace T,Goldberg SN,et al.Percutaneous US-guided radio frequency tissue ablation of liver metastases:treatment and follow upin 16patients[J].Radiology,1997,202:195-203.
[27]Livraghi T,Goldberg SN,Lazzaroni S,et al,Small heptecellular careinoma:treatment with radio-frequency ablation versus ethanol injection[J].Radiology,1999,210:655-657
[28]Gullo CA,Teoh G.Heat shock proteins:to present or not,that is the question[J].Immunol Lett,2004,94:11-15.
[29]Chuma M,Sakamoto M,Yamazaki K,et al.Expression profiling in multistage hepatocarcinogenesis:identification of HSP70 as a molecular marker of early hepatocellular carcinoma[J].Hepatology,2003,37:198-201.
[30]方磊,胡道予.射频消融治疗肝细胞肝癌的长期疗效[J].放射学实践,2007,22(2):113-115.
[31]Takashima M,Kuramit su Y,Yokoyama Y,et al.Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma[J].Proteomics,2003,3:2487-2489.
[1]Lam CM,Ng KK,Poon,et al.Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre[J].British Joumal of Surgery,2004,91:334-338.
[2]Fong Y RL,Jarnagin W,et al.An analysis of 412 cases of hepatocellular carcinoma at a Western center[J].Annats of Surgery,1999,229:790-799.
[3]El Serag,HB Mason AC Rising incidence of hepatocellular carcinomajin the United States.New England Journsl of Medicine 1999;340:745-50.
[4]Livraghi T,Goldberg SN,Lazzaroni S,et al.hepatocellular carcinoma:radio-frequency ablation of medium and large lesions[J].Radiology,2001,136:864-9.
[5]Chen MH,Yang W,Yan K,et al.Large liver tumors protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model overlapping mode and electrode placement process[J].Radiology,2004,232:260-71.
[6]Bleicher RJ,Allegra DP,Nora DT,et al.Radiofrequency ablation in 447complex unresectable liver tumors:lesson leamed[J].Ann Surge Oncol,2003,10:52-58.
[7]严昆,王艳滨,陈敏华,高文,杨薇,戴莹,尹珊珊.172例肝癌射频消融治疗预后因素分析[J].中华医学杂志,2005,85:2322-2326.
[8]Poon RT,Ng KK,Lam CM,et al.Radiofrequency ablation for subcapsular hepatocellular carcinoma[J].Annals of Surgical Oncology,2004,11:281-9.
[9]Yamamoto J,Kosuge T,Takayama T,et al.Recurrence of hepatocellular carcinoma after surger[J]y.British Journal of surgery,1996,83:1219-22.
[10]Nicoli N,Casaril A,Marchiori L,et al.Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation[J].Journal of Hepatobiliary Pancreatic Surgery,2001,8:417-241.
[11]Elias D,de Baere T,Smayra T,et al.Percutaneous radio,frequency thermoablation as an alternative to surgery fortreatment of liver tumour recurrence after hepatectomy[J].British Journal of Surgery,2002,89:752-6.
[12]Choi D,Lim HK,Kim MJ,et al.Recurrent hepatocellular carcinoma:percutaneous radiofrequency ablation after hepatectomy[J].Radiology,2004,230:135-41.
[13]Bowles BJ,Machi J,Limm WM,et al.Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors[J].Archives of Surgery,2001;136:864-869.
[14]Poon RT,Ng KK,Lam CM,et al.Effectiveness of radiofrequency ablation for hepatocellular carcinoma large than 3cm in diameter[J].Achives of surgery,2004;139:281-287.
[15]陈敏华,杨薇,严昆,高文,戴莹,霍苓,张晖,黄信孚,等.应用射频消融法对肝肿瘤患者进行规范化治疗.中华医学杂志,2005,137:1741-1746.
[16]Wu JY,Chen MH,Yan K,Ultrasound-guided radiofrequency ablation in the treatment of liver metastases[J].Peking Uni,2001,33:449-451.
[17]Poon RT,Fan ST,Ng IO,et al.Significance of resection margin in hepatectomy for hepatocellular carcinoma:A critical reappraisal[J].Annals of surgery,2000,231:544-551.
[18]Regimbeau JM,Kianmanesh R,Farges O,et al.Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma[J].Surgery,2002,131:311-317.
[19]Livraghi T,Solbiati L,Meloni MF,et al.Treatment of liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226:441-451.
[20]De Baere T,Risse O,Kuoch V,et al.Adverse events during radiofrequency treatment of 582 hepatic tumors[J]Roentgenol,2003,181:695-700.
[21]Rhim H,Yoon KH,Lee JM,et al.Major complications after radiofrequency thermal ablation of hepatic tumors:spectrum of imaging finding s[J].Radiographics,2003;23:123-134.
[22] Mulier S, Mulier P, Ni Y, et al.Complications of liver tumours[J] . British Journal of Surgery, 2002; 89: 1206-1222.
[23] Rhim H, Yoon KH, Lee JM, et al. Major complications after radiofrequency thermal ablation of hepatic tumors : spectrum of imaging findings[J]. Radiographics, 2003,23: 123-134.
[24] Mulier S, Mulier P, NiY,et al.Complications of radiofrequency coagulation ofliver tumours[J].Br J Surg, 2002,89: 1206-1222.
[25] Bowles BJ, Machi J, LimmWM, et al. Safety and efficacy of radiofrequency themal ablation in advanced livers tumors . Arch Surg, 2001,136: 864—869.
[26] Meloni MF, Goldberg SN, Moser V, et al. Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J]. Eur J Ultrasound, 2002,1573-1576.
[27] Mulier S, Mulier P, Ni Y, et al.Complications of radiofrequency coagulation of liver tumours .Br J Surg, 2002,89: 1206-1222.
[28] Meloni MF, Goldberg SN, Moser V, et al. Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J]. Eur J Ultrasound, 2002, 77:1573-1576.
[29] Livraghi T, Solbiati L, Meloni MF, et al. Treatment of liver tumors with percutaneous radio-frequency ablation : complications encountered in a multicenter study [J]. Radiology, 2003, 226: 441-451.
[30] Rhim H, Yoon KH, Lee JM, et al. Major complications after radiofrequency thermal ablation of hepatic tumors :spectrum of imaging findings[J]. Radiographics, 2003,23: 123-134.
[31] Bowles BJ, Machi J, Limm WM, et al.Safety and efficacy of radiofrequency themal ablation in advanced livers tumors[J] .Arch Surg, 2001,136: 864-869.
[32] De Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow up of more than lyear[J]. AJR AmJ Roentgenol, 2000, 175: 1619-1625.
[33]Rhim H,Yoon KH,Lee JM,et al.Major complications after radiofrequency thermal ablation of hepatic tumors:spectrum of imaging findings[J].Radiographics,2003,23:123-134.
[34]Meloni MF,Goldberg SN,Moser V,et al.Colonic perforation and abscess following radiofrequency ablation treatment liver tumors of hepatoma[J].Eur J Ultrasound,,2002,15:73-76.
[35]戴莹,陈敏华.射频消融在肝肿瘤治疗中的并发症[J].中华外科杂志,2004,42:1193-1195.
[36]Lu DS,Raman SS,Limanond P,et al.lnfluence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors.Journal of Vascular and Interventional Radiology,2003,14:1267-1274.
[37]Kuvshinoff Bw,Ota DM.Radiofrequency ablation of liver tumors:influence of techniqtie and tumor size[J]Surgery,2002;132:605-611.
[38]Siperstein A,Garland A,Engle K,et al.Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors[J].Annals of Surgical Ontology,2000,7:106-113.
[39]Machi J,Uchida S,Sumida K,et al.Ultrasound.guided radio frequency thermal ablation of liver tumors:percutaneous laparoscopic and open surgical approaches[J].Journal of Gastro—intestinal Surgery,2001,5:477-489.
[40]Kosari K,Gomes M,Hunter D,et al.Local intrahepatic and systemic recurrence patterns after radiofiequency ablation of hepatic malignancies[J].Journal of Gastrointestinal Surgery,2002,6:255-263.
[41]arrison LE,Koneru B,Baramipour P,et al.Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma[J]Journal of American College of Surgery,2003,197:759-764.
[42]Hori T,Nagata K,Hasuike S,et al.Risk factors for the local recurrence of heDatOcellular carcinoma after a single session of percutaneous radiofrequency ablation[J].Journa J of Gastroenterology,2003,38:977-981.
[43]Bleicher RJ,Allegra DP,Nora DT,et al.Radiofrequency ablation i11 447 complex unresectable liver tumors:lessons learned[J].Annals of Surgical Oncology,2003,10:52-58.
[44]Komorizono Y,Oketani M,Sako K,et al.Risk factors for local recurrence Of small hepatocellular carcinoma tumors after a single session,single application Of percutaneous radiofrequency ablation[J].Cancer,2003,97:1253-1262.
[45]Elias D,Baton O,Sideris L,et al.Local recurrences after intraoperative radiofrequencv ablation of liver metastases:a comparative study with anatomic and wedge resections[J].Annals of Surgical Oncology,2004,11:500-505.
[46]严昆,陈敏华,杨薇,王艳滨,高文.肝细胞射频消融治疗远期疗效分析[J].中华消化杂志,2006,28:556-558.
[47]Helton WS.Minimizing complications with radiofrequency ablation for liver cancer:the importance of properly controlled clinical trials and standardized reporting[J]Annals of Surgery.2004;239:459-463.
[48]范林军,马宽生,何振平,等.射频消融治疗大肝癌的安全性和近期疗效[J].中国普外基础与临床杂志,2002,9:265-268.
[49]Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular carcinoma:radio-frequency ablation of medium and large lesions[J].Radiology,2000,214:761-768.
[50]张利辉,崔忠,赵清涛,等.射频联合肝动脉栓塞化疗及无水酒精注射治疗不能手术切除肝癌[J].中国普通外科杂志,2002,11:525-527.
[51]Machi J,Uchida S,Sumida K,et al.Ultrasound-guided radiofrequency thermal ablation of liver tumor:percutaneous laparoscopic and open surgical approaches[J].J Gastrointest Surg,2001,5:477-489.
[52]杨薇,陈敏华,严昆,等.射频消融对较大肝肿瘤治疗范围与布针方案计算的研究[J].中华超声影像学杂志,2002,9:265-268.
[53]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治 疗肝细胞癌[J].中华外科杂志,2002,40:826-829.
[54]沈理,陈敏华,严昆,杨薇,高文,廖盛日,杨仁杰等.探讨经皮射频消融联合肝动脉化学栓塞治疗大肝癌的临床应用效果[J].中华超声影像学杂志,2004,13:577-580.
[55]Seegenchmiedt MH,Brady LW,Sauer R.Interstitial thermorad iotherapy:review on technical and clinical aspects.Am[J]Clin Oncol,1990,13:352-363.
[1]Lindquist S.The heat shock response[J].Annu RevBiochem,1986,55:1151-1191.
[2]Heat shock proteins and their characteristics[J].PolMerkrur Lekarski,2005,19(110):215-219.
[3]Sorger PK,LewisMJ,Pelham HR.Heat shock factor is regulated differently in yeast and Hela cells[J].Nature,1987,329(6134):81-84.
[4]Todrvk Sm,Gough M I,Pockley AG.Facets of heat shock protein 70 show immunotherapeutic potential[J].Immunology,2003,110(1):1-9.
[5]胡沛臻,杨守京,马福成,等.人原发性肝细胞癌中热休克蛋白70 mRNA的表达[J].诊断病理学杂志,2001,8:220-223.
[6]尹燕明,秦庆亮,张伟,等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9:84-86.
[7]邓小玲,陈玮,蔡美英,等.原发性肝癌HSP70和MHC Ⅰ类分子的表达[J].临床肝胆病杂志,2003,19:59-61.
[8]Radons I,Multhoff G.Immunostimulatory functions of membrane-bound and exported heat shock protein 70[J].Exerc Immunol Rev,2005,11:17-33.
[9]MaverMP,Bukau B.HSP-70 chaperones:cellular functions and molecular mechanism[J].CellMol Life Sci,2005,62(6):670-684.
[10]Mogk A,Bukau B.Molecular chaperones:structure of a protein disaggregase[J].Curr Biol,2004,20;14(2):R78-80.
[11]van Eden W,van der Zee R,Prakken B.Heat-shock proteins induce T-cell regulation of chronic inflammation[J].Nat Rev Immunol,2005,5(4):318-320.
[12]Molecular chaperones and protein quality control[J].Cell,2006,125(3):443-451.
[13]Cohen JJ.Programmed cell death in the immune system[J].Adv Immunol,1991,50:55-85.
[14]Beere HM,Green DR.Stressmanagement heat shock pro-tein-70 and the regulation of apop tosis[J].Trends Cell Biol,2001,11(1):6-10.
[15]Didelot C,Schmitt E,BrunetM,et al.Heat shock pro teins:endogenousmodulators of apop totic cell death[J].Handb Exp Pharmacol,2006,172:171-198.
[16]YenariMA,L IU I,Zheng Z,et al.Antiapop totic and anti inflammatory mechanisms of heat-shock protein protection[J].Ann N Y Acad Sci,2005,1053:74-83.
[17]Todryk SM,Gough MJ,Pockley A G.Facet s of heatshock protein 70 show immunotherapeutic potential[J].Immunology,2003,110:1-3.
[18] Gross C ,Hansch D , Gastpar R ,et al. Interaction of heat shock protein70 peptide with N K cells involves the N K receptor CD94[J].Biol Chem,2003,384 : 267-269.
[19] Shin BK,Wang H ,Yim AM ,et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function [J]. J BiolChem, 2003 ,278 :7607-7609.
[20] Becket T ,Hartl FU ,Wieland F. CD40 ,an ext racellular receptor for binding and uptake of HSP70-peptide complexes[J]. J Cell Biol ,2002 ,158 (7) :1277-1278.
[21] Wang YF ,Whit tll T ,McGoawan E ,et al. Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells [J] . Immunol , 2005 , 174 :3306-3308.
[22] Ponomarev ED,Tarasenko TN,Sapozlmikov AM.Splenic cvtotoxic cells recognize surface HSP70 on culture-adapted EL24 mouse lymphoma cells [J] . Immunol Lett ,2000,74 (2) :133-135.
[23]Michils A, Redivo M, Zegers2de2Beyl V, et al. Increased expression of high but not low molecular weight heat shock p roteins in respectable lung carcinoma[J]. Lung Cancer, 2001, 33 (1): 59 -67.
[24]Canoz O, Belenli O, Patiroglu T. general features of gastric carcinomas and comparison of HSP70 and NK cell immunoreactivity with p rognostic factors[J]. PathologyOncology Research, 2002, 8 (4) :262-269.
[25]Schueller G, Kettenbach J, Sedivy R, et al. Expression of heat shock p roteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model[J]. Oncol Rep, 2004, 12(3): 495-499.
[26]Schueller G, Kettenbach J, Sedivy R, et al. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo[J]. Int J Oncol, 2004, 24 (3): 609 -613.
[27]Sondermann H, Becker T, Mayhew M, et al. Characterization of a recep tor for heat shock p rotein 70 on macrophages and monocytes[J].Biol Chem, 2000, 381 (12): 1165-1174.
[28]Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apop totic / necrotic tumor cells[J]. Int J Cancer, 2001, 15 (4): 539-548.
[29]Sanchez2Ortiz RF, Tannir N, Ahrar K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radiofrequency ablation of the primary tumor: an in situ tumorvaccine? Urol, 2003,170: 178-179.
[30]Naito Y, Saito K, Shiiba K, et al. CD8 + T cells infiltrated within cancer cells nests as a p rognostic factor in human colorectal cancer [J] .Cancer Res, 1998, 58: 3491-3494.
[31]Noguchi T, Wada S, Takeno S, et al. Lymph node metastasis could be p redicted by evaluation of macrophage infiltration and hsp70 expression in superficial carcinoma of the esophagus[J]. Oncol Rep,2003,10 (5): 1161-1164.